fda came new warning citalopram main point warning citalopram may lead electrocardiogram changes associated abnormal heart rhythm arrhythmia potentially fatal specific change prolongation qtc interval interval correlates total duration ventricular activation recovery citalopram widely used antidepressant medication widely used three reasons likely lot interactions drugs citalopram figured prominently star algorithm largest study done enhancing antidepressant effectiveness third reason generic medication inexpensive psychiatrists broad experience drug general experience well tolerated little toxicity flecainide type ic antiarrhythmic agent indicated prevention paroxysmal atrial fibrillation af paroxysmal supraventricular tachycardia psvt prevention life threatening ventricular arrhythmias like sustained ventricular tachycardia fda warnings drug include proarrhytmic effects excess mortality excess mortality directly observed clinical trial done suppress ventricular arrhythmias black box warnings drug listed directly medline looking safety concerns medications important differences emerge first fda recommends maximum doses citalopram maximum dose adults specific conditions including aging searching fda web site shows exactly references safety concerns flecainide none contain level information second citalopram warning shows table qtc interval changes dose citalopram escitalopram information fda documents i could find flecainide even though widely accepted flecainide causes dose related changes qtc interval also qrs pr intervals along host additional effects cardiac pacemakers conduction overall tone release citalopram potentially cardiotoxic drug third ecg monitoring recommendations internally consistent absolute cut qtc interval ms highly unlikely even cases patient taking mg per day citalopram also unlikely qtc intervals citalopram warning lead qtc interval greater ms result tens thousands ecgs done way qtc interval determined black box warnings recently issued warning considered serious questions raised relative drugs known cardiotoxicity whole issue qtc warnings psychiatric drugs certainly nobody wants rare severe complication result prescription medication really avoided good would ecg screening trials address issue whether patients taking citalopram need baseline ecgs patients taking flecainide probably multiple ecgs done indicate possible need treatment little guidance ecg issue many patients taking flecainide patients get serial ecgs exercise stress tests rule proarrhythmic effects precautions needed patients citalopram thresholds treatment different given fact flecainide caused increased mortality clinical trials citalopram would argument flecainide used treat life threatening arrhythmias indication prevention atrial fibrillation atrial fibrillation life threatening arrhythmia regard seriousness diagnosis major depression carries lifetime mortality finally table relationship flecainide dose qtc prolongation like see citalopram escitalopram possible flecainide effect throughout dosage range citalopram serious questions given i already established significant bias media psychiatry psychiatrists psychiatric medications recent fda warning created lot anxiety psychiatrists patient taking citalopram majority patients seen primary care physicians citalopram cardiotoxic let see evidence let see compares medication known cardiotoxicity let level warning medications concrete ideas needs done manage risk george dawson md dfapa